# Effect of the GSK2245035 on the Allergen-induced Asthmatic Response

> **NCT02833974** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 36 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GSK2245035 Nasal Spray Solution
- **DRUG:** Placebo Nasal Spray Solution

## Key facts

- **NCT ID:** NCT02833974
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-05
- **Primary completion:** 2018-02-14
- **Final completion:** 2018-05-04
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2021-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02833974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02833974, "Effect of the GSK2245035 on the Allergen-induced Asthmatic Response". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02833974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*